Paul J F Rider1, Ifeanyi K Uche1, Larissa Sweeny1,2, Konstantin G Kousoulas1. 1. Division of Biotechnology and Molecular Medicine and Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA. 2. Louisiana State University Health Sciences Center, New Orleans, Louisiana USA.
Abstract
PURPOSE OF REVIEW: The design of novel herpes simplex type I (HSV-1)-derived oncolytic virotherapies is a balancing act between safety, immunogenicity and replicative potential. We have undertaken this review to better understand how these considerations can be incorporated into rational approaches to the design of novel herpesvirus oncolytic virotherapies. RECENT FINDINGS: Several recent papers have demonstrated that enhancing the potential of HSV-1 oncolytic viruses to combat anti-viral mechanisms present in the tumor microenvironment leads to greater efficacy than their parental viruses. SUMMARY: It is not entirely clear how the immunosuppressive tumor microenvironment affects oncolytic viral replication and spread within tumors. Recent work has shown that the manipulation of specific cellular and molecular mechanisms of immunosuppression operating within the tumor microenvironment can enhance the efficacy of oncolytic virotherapy. We anticipate that future work will integrate greater knowledge of immunosuppression in tumor microenvironments with design of oncolytic virotherapies.
PURPOSE OF REVIEW: The design of novel herpes simplex type I (HSV-1)-derived oncolytic virotherapies is a balancing act between safety, immunogenicity and replicative potential. We have undertaken this review to better understand how these considerations can be incorporated into rational approaches to the design of novel herpesvirus oncolytic virotherapies. RECENT FINDINGS: Several recent papers have demonstrated that enhancing the potential of HSV-1 oncolytic viruses to combat anti-viral mechanisms present in the tumor microenvironment leads to greater efficacy than their parental viruses. SUMMARY: It is not entirely clear how the immunosuppressive tumor microenvironment affects oncolytic viral replication and spread within tumors. Recent work has shown that the manipulation of specific cellular and molecular mechanisms of immunosuppression operating within the tumor microenvironment can enhance the efficacy of oncolytic virotherapy. We anticipate that future work will integrate greater knowledge of immunosuppression in tumor microenvironments with design of oncolytic virotherapies.
Authors: Daniele V F Tauriello; Sergio Palomo-Ponce; Diana Stork; Antonio Berenguer-Llergo; Jordi Badia-Ramentol; Mar Iglesias; Marta Sevillano; Sales Ibiza; Adrià Cañellas; Xavier Hernando-Momblona; Daniel Byrom; Joan A Matarin; Alexandre Calon; Elisa I Rivas; Angel R Nebreda; Antoni Riera; Camille Stephan-Otto Attolini; Eduard Batlle Journal: Nature Date: 2018-02-14 Impact factor: 49.962
Authors: Nithya Jambunathan; Anu-Susan Charles; Ramesh Subramanian; Ahmad A Saied; Misagh Naderi; Paul Rider; Michal Brylinski; Vladimir N Chouljenko; Konstantin G Kousoulas Journal: J Virol Date: 2015-12-09 Impact factor: 5.103
Authors: Amy Haseley Thorne; Walter H Meisen; Luke Russell; Ji Young Yoo; Chelsea M Bolyard; Justin D Lathia; Jeremy Rich; Vinay K Puduvalli; Hsiaoyin Mao; Jianhua Yu; Michael A Caligiuri; Susheela Tridandapani; Balveen Kaur Journal: Mol Ther Date: 2014-06-04 Impact factor: 11.454
Authors: Aldo Pourchet; Steven R Fuhrmann; Karsten A Pilones; Sandra Demaria; Alan B Frey; Matthew Mulvey; Ian Mohr Journal: EBioMedicine Date: 2016-01-19 Impact factor: 8.143